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significantly contributes to maternal and foetal morbidity
and mortality. In this study, we used a nonbiased
microarray approach to identify novel circulating miRNAs in
maternal plasma that may be associated with
preeclampsia.
Methods: Plasma samples were obtained at 16 and 28
weeks of gestation from 18 women who later developed
preeclampsia (cases) and 18 matched women with
normotensive pregnancies (controls). We studied miRNA
expression profiles in plasma and subsequently confirmed
miRNA and target gene expression in placenta samples.
Placental samples were obtained from an independent
cohort of 19 women with preeclampsia matched with 19
women with normotensive pregnancies.
Results: From the microarray, we identified one miRNA
that was significantly differentially expressed between
cases and controls at 16 weeks of gestation and six
miRNAs that were significantly differentially expressed at
28 weeks. Following qPCR validation, only one miR-206
was found to be significantly increased in 28-week
samples in women who later developed preeclampsia
(1.4-fold change0.2). The trend for increase in miR-206
expression was mirrored within placental tissue from
women with preeclampsia. In parallel, IGF-1, a target gene
of miR-206, was also found to be downregulated
(0.410.04) in placental tissue from women with
preeclampsia. miR-206 expression was also detectable in
myometrium tissue and trophoblast cell lines.
Conclusion: Our pilot study has identified miRNA-206 as a
novel factor upregulated in preeclampsia within the
maternal circulation and in placental tissue.
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reeclampsia is a syndrome that occurs during the
second half of pregnancy in approximately 1–5%
of women in the developed world [1]. Preeclampsia
is broadly defined by the International Society for the
Study of Hypertension in Pregnancy (ISSHP) as de-novo
development of hypertension and proteinuria after the 20th Copyright © 2015 Wolters Kluwe
2068 www.jhypertension.comweek of gestation. The disease contributes to maternal and
perinatal morbidity and mortality as well as conferring
increased long-term risk of chronic illnesses. The only
effective treatment is delivery both of the baby and the
placenta; therefore, the basis of the disease is thought to be
predominantly due to placental dysfunction. The develop-
ment of preeclampsia is multifactorial and remains incom-
pletely understood.
MicroRNAs (miRNAs) are small noncoding RNAs that act
at a posttranscriptional level to degrade target genes rec-
ognised by complementary base pairing in the 3’ untrans-
lated region of the mRNA. miRNAs may provide a novel
strategy for better understanding of preeclampsia and its
diagnosis. miRNAs have been shown to play a functional
role in physiological processes important in pregnancy
such as placental development, trophoblast proliferation
and migration and angiogenesis [2]. miRNAs also exist in
circulation within a number of body fluids. Currently, the
origin of circulating miRNAs is not fully understood and
therefore it is not known how their levels are altered in
disease, or if they have a particular target via which they can
exert a functional role. Circulating miRNAs are protected
from degradation by specific proteins [3,4] within exosomes
[5] or microparticles [6]. This suggests that miRNA in plasma
may serve an important role requiring their integrity to be
preserved. Few studies into preeclampsia have assessed
levels of circulating miRNAs in the plasma and have either
focused on late gestation or have lacked translation into
relevant tissues [7–9].
Microarray technology allows the expression of many
miRNAs to be detected simultaneously creating a patient-
specific profile. In this pilot study, we have used an Open-
Array microarray to complete a nonbiased screen ofr Health, Inc. All rights reserved.
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miR-206 expression in preeclampsiacirculating miRNA expression in plasma samples taken
from 18 women who developed preeclampsia and 18
matched women with normotensive pregnancies at 16
and 28 weeks of gestation. We hypothesized that there
are detectable changes in circulating miRNA expression at
the preclinical stage of preeclampsia. Our aim was to
identify these miRNAs and evaluate their relevance as an
early biomarker and their potential pathological role
in disease.
MATERIALS ANDMETHODS
Patients
Proteomics in pre-eclampsia cohort
For the microarray study, plasma samples from women
recruited between 2007 and 2010 as part of the prospective
‘Proteomics in Preeclampsia’ (PIP) study were used. The
study protocol has been described elsewhere [10]; in brief,
over 4000 women were recruited across Glasgow at their
initial antenatal hospital appointment. Further samples
were obtained from 180 women with two or more risk
factors for preeclampsia (nulliparity, age over 35 years, BMI
>30 kg/m2, family history of preeclampsia in mother or
sister [11]), at gestational weeks 16 and 28. All women were
followed until delivery, when pregnancy outcomes were
obtained from labour ward databases and hospital case
records. Of thewomen sampled at gestational weeks 16 and
28, 18 (10%) developed preeclampsia and were matched
for age, BMI and parity with 18 women who had normo-
tensive pregnancies. Plasma samples were stored at 808C
until analysis.
Placental and myometrium tissue cohort
Placental biopsies were collected at delivery from a second
cohort, independent from the PIP study, of 38 women, 19 of
whom were diagnosed with preeclampsia according to
ISSHP criteria and 19 normotensive individuals matched
for age, BMI and parity. Myometrium specimens were
obtained from a third independent cohort wherein all
women were normotensive. Myometrium biopsies were
taken from the upper margin of the lower segment uterine
incision during caesarean section in women who delivered
at term (>37 weeks’ gestation: n¼ 3 before the onset of
labour and n¼ 3 in labour) and preterm (defined as 24–36
weeks: n¼ 2 before the onset of labour). All of the women
in the preterm group were delivered preterm due to pre-
eclampsia. In the term group, caesarean section was due to
breech position (n¼ 2) or prior elective caesarean section
(n¼ 7). In both groups, individual characteristics were
recorded at the time of tissue collection and delivery details
were recorded from patient notes. Customized birth weight
centiles were calculated using the Gestation NetworkCen-
tile Calculator 5.4 (http://www.gestation.net/birthweight_-
centiles/centile_online.htm). All biopsies were flash frozen
in liquid nitrogen and stored at 808C until analysis.
The PIP Study and the collection of placenta and myo-
metrium tissue were approved by the West of Scotland
Research Ethics Committee and adhere to the principles of
the Declaration of Helsinki. All participants gave written
informed consent. Copyright © 2015 Wolters Kluwer
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BeWo cells (Cat. No. CCL-98) and JAR cells (Cat. No. HTB-
144) were maintained in Ham’s F12Kmedium andmodified
RPMI-1640 medium, respectively, in 5% CO2 at 378C (all
cells and media from ATCC). Both media were supple-
mented with foetal calf serum (10%), penicillin/streptomy-
cin (1%), 200mmol/l L-glutamine (1%) and Fungizone (1%).
C2C12 cells were maintained in Dulbecco’s modified Eagle
medium (DMEM; Invitrogen, Paisley, USA) supplemented
with foetal calf serum (10%), 200mmol/l L-glutamine (1%)
and penicillin/streptomycin (1%). Confluent cultures were
subject to a 1 : 3 subcultivation ratio using trypsin/ PBS.
RNA extraction
RNA extraction from plasma, cells and tissues was per-
formed using the miRNeasy mini kit (Qiagen, Hilden,
Germany) according to manufacturer’s instructions.
Samples were processed according to manufacturer’s pro-
tocol. Each sample’s total RNA concentration was deter-
mined by Nanodrop (Thermo Fisher Scientific, Paisley, UK)
and total RNA was stored at 808C.
MicroRNA profiling by OpenArray
The OpenArray real-time PCR system (Applied Biosystems/
LifeTechnologies, Paisley,UK)wasused to screen formiRNA
expression levels in plasma. Total RNA from patient plasma
samples was processed according to manufacturer’s instruc-
tions, using the low input modifications for blood plasma
samples. Briefly, reverse transcription of each sample was
carried out with two separate primer pools in parallel, using
19.15ng of total RNA per sample per reaction. Following
reverse transcription, a preamplification step with 16 cycles
was carried out and the resulting products diluted 1 : 20. The
diluted samples, matched and grouped, were applied to
OpenArray qPCR panels in a randomized fashion, for profil-
ing of 754 miRNAs per sample. Before calculating the Ct
values for each miRNA with the supplied software (Life
Technologies), the default minimum fluorescence signal
threshold was adjusted to 200 and the ‘subtract baseline’
method was applied. Prior to comparing miRNA expression
levels, any miRNA probes on the array panels that did not
meet the quality control criteriawere excluded fromanalysis.
Ct values from the microarray were not subject to normal-
ization, as suitable stablemiRNAs could not be found. There-
fore, all statistical analysis was performed on raw Ct values
presented in the text. miRNAs with a Ct of 35 or above were
not included in analysis.
Reverse transcriptase PCR
Gene expression RT-PCR was performed using the Taqman
Reverse Transcription Kit (Applied Biosystems) according
to manufacturer’s instructions with 400 ng RNA input. The
reaction was run on a Multi Block System Satellite 0.2
Thermo Cooler (Thermo Fisher Scientific) on the following
settings: 258C 10min, 488C 30min, 958C 5min. miRNA RT-
PCR was performed using the Taqman miRNA Reverse
Transcription Kit (Applied Biosystems) according to man-
ufacturer’s instructions with 5 ng initial RNA input. The
reaction was run on a Multi Block System Satellite 0.2
Thermo Cooler (Thermo Fisher Scientific) on the following
settings: 168C, 30min; 428C, 30min; 858C, 5min. Health, Inc. All rights reserved.
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Reactions were set up using the following reagents: Taq-
man Universal Mastermix (Applied Biosystems), dH2O and
relevant Taqman probe (Applied Biosystems). miRNA pro-
tocol was run on an ABI PRISM 7900HT PCR system at the
following settings: 958C, 10min; followed by 40 cycles of
958C, 15 s; 608C, 1min. Gene expression protocol was run
on an ABI PRISM 7900HT PCR system at the following
settings: 958C, 15min; followed by 40 cycles of 958C, 15 s;
608C, 1min. miRNA results were normalized using syn-cel-
miR 39 as a spiked-in reference miRNA. PPIA, TOP1 and
GAPDH were chosen as reference genes for gene expres-
sion studies [12]. In order to obtain more robust results than
with a single reference gene, gene expression in placenta
was normalized to the geometric mean of all three reference
genes [13]. PPIA, TOP1 and GAPDH were chosen as refer-
ence genes for gene expression studies. Ct values were
analysed using the 2(-delta delta Ct) method, with dCt
indicating normalization to the geometric mean of the three
reference genes.
Statistical analysis
All data are represented standard error of the mean
(SEM). Parameters measured in patient cohorts, miRNA
changes identified from the microarray and all qPCR data
were analysed using a Student’s t-test where P< 0.05,
P< 0.01 and P< 0.001.
RESULTS
miRNA-206 is differentially regulated in plasma
from women who later developed
preeclampsia
Plasma samples collected at 16 and 28 weeks gestation from
18 women who went on to develop preeclampsia and 18
matched normotensive women (Table 1) were subject to
miRNA OpenArray analysis. Of the 754 miRNAs present on
the microarray, 465 were detectable in the cohort plasma
samples (Supp. Table 1, http://links.lww.com/HJH/A495).
Following statistical analysis of the microarray data, six
miRNAs were found to be significantly differentially Copyright © 2015 Wolters Kluwe
TABLE 1. Characteristics of women in the microarray study cohort
Cases (n¼
Age (years) 315.3
BMI (kg/m2) 29.95.3
Smoker (n) 1 (5.5%)
Nulliparous 16 (88.8%
Previous preeclampsia 0
Family history (mother or sister) of preeclampsia 6 (33.3%
SBP 16 weeks gestation (mmHg) 12610
DBP 16 weeks gestation (mmHg) 818
SBP 28 weeks gestation (mmHg) 12910
DBP 28 weeks gestation (mmHg) 818
Caesarean section (n) 4 (22.2%
Gestation at delivery (weeks) 38.92
Birth weight (g) 313442
Plasma samples taken at 16 and 28 weeks gestation from 18 women who developed preeclam
(n¼16 primigravidae) to 18 women who had normotensive pregnancies (controls). Data are pr
P<0.05.
P<0.01.
2070 www.jhypertension.comexpressed between the case and control groups at either
time point (Fig. 1a). The only miRNA found to be differ-
entially expressed at 16 weeks’ gestation was miR-23a,
which was found to be decreased in women who went on
to develop preeclampsia. The other five miRNAs identified
from the OpenArray (196b-5p, 206-5p, 502-5p, 503-5p and
758-3p) all had increased expression in cases at 28 weeks of
gestation only. Following these findings, the six miRNAs
identified by the microarray were subject to standard qPCR
validation. There were no significant differences in expres-
sion between cases and controls in miR-23a in plasma
samples taken at 16 weeks (Supp. Figure 1a, http://links.
lww.com/HJH/A495). Of the differences in expression
between cases and controls detected by the microarray
at 28 weeks, only miR-206 was found to be significantly
different between the groups in validation experiments
(Fig. 1b and Supp. Figure 1b, http://links.lww.com/HJH/
A495). In keeping with the microarray data, miR-206 was
found to be upregulated inwomenwhowent on to develop
preeclampsia (1.4-fold change 0.2) compared with those
with normotensive pregnancies.
miR-206 and a group of its target genes are
differentially expressed in term placental tissue
from women with preeclampsia
Following the discovery of miR-206 dysregulation in the
circulation ofwomenwhowent on to develop preeclampsia,
the next step was to investigate this miRNA in other tissues
that have pregnancy-specific relevance. Placental samples
were collected at delivery from women with preeclampsia
(n¼ 19) and matched women with normotensive pregnan-
cies (n¼ 19) (Table 2). The higher miR-206 expression seen
in plasma from cases is a trend, which is mirrored in the
placental tissue (Fig. 2a). Although themagnitude of increase
in miR-206 in placenta (1.44-fold change 0.25) compared
with the control group is similar to that seen for plasma, it did
not reach statistical significance (P¼ 0.11) (Fig. 2a).
Interrogation of the miRNA databases TARGETSCAN-
VERT [14] and miRbase [15] revealed that miR-206 targets
a number of relevant genes known to be dysregulated
in preeclampsia. To investigate whether expression ofr Health, Inc. All rights reserved.
18) Controls (n¼18) P
315.4 NS
29.94.4 NS
3 (16.6%) NS
) 15 (83.3%) NS
0 NS
) 1 (5.5%) 0.09
1239 NS
767 0.004
1239 0.043
767 0.045
) 3 (16.6%) NS
40.21.7 0.046
1 3632685 0.013
psia (cases) were matched for age (30.61.3 years), BMI (29.41 kg/m2) and parity
esented as mean standard deviation.
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FIGURE 1 Microarray analysis shows differential miRNA expression in plasma between women who went on to develop preeclampsia and normotensive controls. (a) Six
miRNAs were found to be differentially regulated between women who went on to develop preeclampsia (PE) and controls from the microarray. (b) qPCR validation shows
that miR-206 expression is significantly higher in plasma samples at 28 weeks’ gestation in women who went on to develop preeclampsia, than those who did not. Raw
Ct values are shown above the bar.
miR-206 expression in preeclampsiagenes targeted by miR-206 differed in preeclampsia, the
expression of vascular endothelial growth factor (VEGF),
insulin-like growth factor 1 (IGF-1) and neurogenic locus
notch homolog 3 (NOTCH-3) was also measured in the
same placental tissue (Fig. 2b). There was no significant
difference inNOTCH-3 expression between placental tissue
from women with preeclampsia and controls. However,
two genes regulated by miR-206 were found to be differ-
entially expressed in placental tissue. There was a signifi-
cant upregulation of VEGF in placental tissue from women Copyright © 2015 Wolters Kluwer
TABLE 2. Characteristics of the placental tissue cohort
Cases (n¼19)
Age (years) 295.4
BMI (kg/m2) 29.56.8
Smoker (n) 4 (21.1%)
Nulliparous 11
Third trimester SBP (mmHg) 14825
Third trimester DBP (mmHg) 9316
Gestation at delivery (weeks) 35.93.2
Birth weight (g) 2463840
Placental samples taken at delivery from 19 women with preeclampsia (cases) were matched fo
pregnancies (controls). Women with preeclampsia from this cohort, on average, delivered befor
P<0.05.
P<0.01.
P<0.001.
Journal of Hypertensionwith preeclampsia (2.28-fold change 0.45). IGF-1 was
found to be significantly downregulated in placental tissue
from cases (0.41-fold change 0.04).
Further investigation of miR-206 in pregnancy related
tissues showed that miR-206 was detectable in both preterm
women with re-eclampsia (n¼ 2) and term myometrium
(n¼ 9) from normotensive women (Supp. Figure 2a, http://
links.lww.com/HJH/A495). miR-206 expression was also
detected in two trophoblast cell lines, BeWo and JAR (Supp.
Figure 2b, http://links.lww.com/HJH/A495). Health, Inc. All rights reserved.
Controls (n¼19) P
304.6 NS
29.46.7 NS
5 (26.3%) NS
8 NS
12319 0.001
739.4 0.00005
39.41.5 0.0001
3573652 0.00006
r age (29.70.7 years) and BMI (29.4 6kg/m2) to 18 women who had normotensive
e full term. Data are presented as mean standard deviation.
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FIGURE 2 miR-206 and a group of target genes are dysregulated in placental
tissue in women with preeclampsia. (a) miR-206 is higher in placental tissue of
women with preeclampsia (P¼0.11). Raw Ct values are shown above the bar.
(b) Targets of miR-206, VEGF-A and IGF-1 are differentially regulated in placental
tissue.
Akehurst et al.DISCUSSION
In this pilot study, we aimed to use a nonbiased microarray
approach to identify novel circulating miRNAs that are
associated with preeclampsia. The microarray data showed
that, amongst others, miR-206 expression was significantly
increased at 28 weeks of gestation in plasma from women
who later developed preeclampsia compared with those
who did not. This difference inmiR-206 expression is robust
following qPCR validation. Furthermore, we have been
able to translate this difference in circulation to biologically
relevant cells and tissues. miR-206 expression is also upre-
gulated in placental tissue from an independent cohort of
women with preeclampsia. We consider this to be a major
strength of this study. There was also a significant down-
regulation of a clinically relevant target gene, IGF-1, and an
upregulation of another target gene VEGF. In addition, miR-
206 was detectable in the myometrium and two human
trophoblast cell lines confirming its presence in relevant
tissues and supporting a potentially pathological role. Copyright © 2015 Wolters Kluwe
2072 www.jhypertension.comIn this study, we were able to validate the change in
expression in one of five miRNAs found to be differentially
regulated at 28 weeks from the microarray, miR-206. Per-
haps in a larger cohort, we would have had more power to
identify these changes at this validation stage. The change
in miR-23a identified in the microarray at 16 weeks was not
validated by qPCR. This is perhaps not surprising, as
another study by Luque et al. [7], which looked as early
as the first trimester of pregnancy, did not see any signifi-
cant changes in expression either. This suggests that circu-
lating miRNAs may not play a role in the pathogenesis of
preeclampsia until later in pregnancy.
miR-206 is predominantly expressed in skeletal muscle
and is part of the ‘myomiR’ family of miRNAs known to
function in myogenesis and striated muscle growth and
repair [16]. It is widely considered that miR-206 is exclu-
sively expressed in skeletal muscle; however, our findings
show that this is not the case. miR-206 is expressed from an
intergenic region of chromosome 6 as a bicistronic trans-
cript that also includes another myomiR, miR-133b. As a
myomiR, accordingly, miR-206 has been found to be dys-
regulated in diseases wherein muscular dystrophy is a
central mechanism [17]. However, miR-206 has also been
reported to be mechanistically involved in cancer pro-
gression [18], neurological disease [19] and myocardial
infarction [20]. This is the first study to define a role for
miR-206 in pregnancy or preeclampsia. With respect to
preeclampsia, the genomic landscape in which miR-206
is found is of interest. Downstream of miR-206 is the
interleukin 17a (IL17a) gene that expresses IL-17, a potent
cytokine mediating pro-inflammatory responses [21]. T-
helper cells that produce IL-17 (TH17) have been shown
to be increased in the circulation of women with pree-
clampsia [22]. In the same study, the cytokine itself is also
found to be increased in the circulation of a rodent model of
preeclampsia [22]. Whether the transcription of IL-17 and
miR-206 are related is speculation but warrant further
investigation.
Our findings show that miR-206 expression was
observed to be higher in both the circulation and the
placenta and is therefore a promising candidate for further
study. Notably, it has experimentally validated interactions
with a number of genes known to be directly involved in
the pathology of preeclampsia, particularly at the placenta:
VEGF [23,24], NOTCH-3 [25,26], IGF-1 [20] and hypoxia
inducible factor 1 a (HIF-1a) [27]. In our study, we have
shown that VEGF mRNA expression is upregulated in
placental tissue from women with preeclampsia. This has
been shown in other studies [28] and is thought to be a
physiological response to hypoxia in the placenta. miRNAs
are ‘fine-tuners’ of gene expression having small effects on
large numbers of genes. miR-206 may therefore be involved
in the regulation of VEGF expression in response to
hypoxia.
Placental IGF-1mRNA expression was downregulated in
placental tissue in preeclampsia in the present study. miR-
206 has been previously been shown to target and down-
regulate IGF-1 expression in other tissues, specifically rat
myoblasts [20]. It is well established that maternal IGF-1 has
important growth effects on the foetus [29] and myometrial
vasculature [30], which are relevant processes to the causer Health, Inc. All rights reserved.
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miR-206 expression in preeclampsiaof preeclampsia. Paradoxically, the only study that has
looked at IGF-1 protein levels in the circulation showed
an increased level of IGF-1 in the first and second trimester
of pregnancy in preeclampsia [31]. It is not surprising to see
conflicting results between the placenta and maternal circu-
lation, as these are both governed by different processes.
Tissue gene expression can be upregulated in order to exert
local effects that are not excreted into the vasculature. Sim-
ilarly, thematernal circulation is affected by shedding from all
the major organs in the body as well as circulating vesicles
such as exosomes and microparticles. The similar degree of
upregulation of maternal plasma and placental miR-206
observed in the present study could suggest that maternal
plasma miR-206 levels may originate from the placenta.
One of the strengths of our study is the screening of
samples from two gestational time points, 16 and 28 weeks,
both before the clinical signs of preeclampsia were appa-
rent, whereas other studies using large-scale approaches
such as microarray or next generation sequencing have
only looked at one gestational timepoint [32–35]. Our study
is also unique in that changes detected in the circulation by
microarray have been corroborated in placental tissue from
an independent cohort. Previous studies have looked at
circulating miRNAs or tissue miRNAs exclusively without an
overlap between the two. Circulating miRNAs have been
measured in umbilical cord plasma [36], although other
screens have been carried out in tissues such as the placenta
[37] and trophoblasts [38].
It is unknown from our work whether the increase seen
in miR-206 is a cause or effect of preeclampsia. Therefore, it
can only be considered as a starting point in order to further
investigate novel mechanisms of the disease. As the
changes identified in our study were only seen at 28 weeks
of gestation and not at an earlier time point, miR-206
upregulationmay be a response to the established placental
hypoxia characteristic of preeclampsia. We hypothesize
that the hypoxic response leads to a compensatory increase
in VEGF causing a parallel increase in its negative regulator,
miR-206. This then results in changes in expression of other
placental genes regulated by miR-206 such as IGF-1. Nota-
bly, placental expression of miR-206 was upregulated to a
similar degree but did not reach statistical significance. We
suggest that there are two reasons for this within our study.
Firstly, the placenta is a diverse tissue formed by the
cooperation of many different cell types. Secondly, our
placental samples were representative of the entire tissue
and not specific regions. It has previously been shown that
miRNA levels can vary according to the region of placenta
that is sampled [39]. Therefore, significant changes in miR-
206 expression in one area could have been masked by
nonsignificant changes in the other. A future improvement
on our study is to allow for this diversity and analyse
expression profiles in further dissected parts of the tissue
in order for us to make a more specific statement about
where such changes occur. Further to this, miRNAs are fine-
tuners of gene expression; thus, changes in their expression
are accordingly rapid and transient within a tissue. It may be
difficult to capture miRNA upregulation at any given point
in time within a tissue for such reasons, making it difficult to
collect expression data without an intrinsic element of
variability. Placental samples used were also not matched Copyright © 2015 Wolters Kluwer
Journal of Hypertensionfor gestational age. This is a generic limitation of such
studies, as tissues and bloods cannot be matched for
different gestational time points. Further analysis of our
expression data in placental tissue shows no significant
correlation between expression and gestational day of
delivery (Supp. Figure 3, http://links.lww.com/HJH/A495).
conclusion, earlier diagnosis and better understanding of
the disease of preeclampsia is at the forefront of preeclamp-
sia research. Our study has identified miR-206 as a novel
differentially regulated miRNA in preeclampsia that may
give information regarding the pathology of the disease. As
this is a pilot study, a large independent cohort is needed to
determine whether the small increase in miR-206 expres-
sion seen is reproducible and, if so, provides further insight
into the complex disease of preeclampsia.
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Reviewer 1
This study represents a preliminary step to shed light into the
pathogenesis of preeclampsia and the role of microRNAs.
Reviewer 2
Strengths: The pathophysiology of preeclampsia remains
not well defined and the existence of regional differences in
the etiology of the preeclampsia has been proposed. Thisarticle identified miRNA-206 as a novel factor up-regulated
in preeclampsia within the maternal circulation and in
placental tissue. New multi centric, collaborative studies
will be necessary to understand the real importance of
circulating miRNAs in maternal plasma that may be associ-
ated with preeclampsia.
Weaknesses: Small number of patients that confers to
this study the characteristics of a pilot study. It will be
necessary to define the probable role of the association of
microRNA-206 with down-regulation of IGF-1.r Health, Inc. All rights reserved.
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